These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21317681)

  • 1. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections.
    Abdel-Rahman SM; Chandorkar G; Akins RL; Bradley JS; Jacobs RF; Donovan J; Benziger DP
    Pediatr Infect Dis J; 2011 Aug; 30(8):712-4. PubMed ID: 21317681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.
    Abdel-Rahman SM; Benziger DP; Jacobs RF; Jafri HS; Hong EF; Kearns GL
    Pediatr Infect Dis J; 2008 Apr; 27(4):330-4. PubMed ID: 18316988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers.
    Dvorchik B; Damphousse D
    J Clin Pharmacol; 2004 Jun; 44(6):612-20. PubMed ID: 15145969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
    Benvenuto M; Benziger DP; Yankelev S; Vigliani G
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3245-9. PubMed ID: 17005801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moderate liver impairment has no influence on daptomycin pharmacokinetics.
    Dvorchik B
    J Clin Pharmacol; 2004 Jul; 44(7):715-22. PubMed ID: 15199076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.
    Di Paolo A; Tascini C; Polillo M; Gemignani G; Nielsen EI; Bocci G; Karlsson MO; Menichetti F; Danesi R
    Int J Antimicrob Agents; 2013 Sep; 42(3):250-5. PubMed ID: 23891432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure].
    Sarriá Cepeda C
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():38-42. PubMed ID: 22541974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
    Benziger DP; Pertel PE; Donovan J; Yankelev S; Schwab RJ; Swan SK; Cannon C
    Clin Nephrol; 2011 Jan; 75(1):63-9. PubMed ID: 21176752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age.
    Bradley JS; Benziger D; Bokesch P; Jacobs R
    Pediatr Infect Dis J; 2014 Sep; 33(9):936-9. PubMed ID: 25361023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration.
    Wenisch JM; Meyer B; Fuhrmann V; Saria K; Zuba C; Dittrich P; Thalhammer F
    J Antimicrob Chemother; 2012 Apr; 67(4):977-83. PubMed ID: 22210754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.
    Traunmüller F; Schintler MV; Metzler J; Spendel S; Mauric O; Popovic M; Konz KH; Scharnagl E; Joukhadar C
    J Antimicrob Chemother; 2010 Jun; 65(6):1252-7. PubMed ID: 20375031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.
    Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I
    Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin in paediatrics: current knowledge and the need for future research.
    Principi N; Caironi M; Venturini F; Pani L; Esposito S
    J Antimicrob Chemother; 2015 Mar; 70(3):643-8. PubMed ID: 25406298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.
    Vilay AM; Grio M; Depestel DD; Sowinski KM; Gao L; Heung M; Salama NN; Mueller BA
    Crit Care Med; 2011 Jan; 39(1):19-25. PubMed ID: 20890189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin.
    Prescrire Int; 2007 Dec; 16(92):245. PubMed ID: 18095389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of daptomycin in patients receiving hemodialysis.
    Mueller BA; Crompton JA; Donovan BJ; Yankalev S; Lamp KC
    Pharmacotherapy; 2011 Jul; 31(7):665-72. PubMed ID: 21923453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of intravitreal daptomycin in uveitis-induced rabbit model.
    Ozcimen M; Sakarya Y; Ozcimen S; Sakarya R; Goktas S; Iyisoy S; Alpfidan I; Erdogan E
    Curr Eye Res; 2015 May; 40(6):598-603. PubMed ID: 25110947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
    Figueroa DA; Mangini E; Amodio-Groton M; Vardianos B; Melchert A; Fana C; Wehbeh W; Urban CM; Segal-Maurer S
    Clin Infect Dis; 2009 Jul; 49(2):177-80. PubMed ID: 19500039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.